KRM22 (LON:KRM – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported GBX (0.50) earnings per share (EPS) for the quarter, Digital Look Earnings reports. KRM22 had a negative net margin of 9.45% and a negative return on equity of 14.95%.
KRM22 Price Performance
Shares of KRM22 stock traded down GBX 0.50 during trading on Friday, reaching GBX 34. 258 shares of the company’s stock were exchanged, compared to its average volume of 132,606. The company has a debt-to-equity ratio of 5.03, a quick ratio of 1.15 and a current ratio of 0.87. KRM22 has a 1-year low of GBX 27 and a 1-year high of GBX 48.50. The company has a market cap of £20.17 million, a P/E ratio of -6.67 and a beta of -0.15. The firm’s 50-day moving average price is GBX 33.74 and its 200 day moving average price is GBX 35.17.
Insider Activity
In other KRM22 news, insider Thomas Keith Todd bought 350,000 shares of the stock in a transaction on Thursday, August 20th. The stock was purchased at an average price of GBX 28 per share, with a total value of £98,000. Also, insider Garry Jones bought 17,500 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was bought at an average cost of GBX 28 per share, with a total value of £4,900. Insiders purchased 392,500 shares of company stock worth $11,215,000 over the last ninety days. 18.80% of the stock is currently owned by insiders.
KRM22 Company Profile
At KRM22, we believe in a world in which organisations operate at their optimal threshold of risk to drive increased returns. We develop outstanding products built and delivered through a Global Risk Platform, to bring increased visibility and lower cost management to capital market organisations.
Featured Articles
- Five stocks we like better than KRM22
- Remitly’s September Pullback Tests a Still-Strong Growth Story
- Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
- Why Concentra’s Quiet Healthcare Business Keeps Winning
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Receive News & Ratings for KRM22 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KRM22 and related companies with MarketBeat.com's FREE daily email newsletter.
